Collaborations & Alliances
Related Searches:
Filter by:
541 - 555 of 1091 results
September 14, 2010
Genmab and Seattle Genetics (SGI) have entered into an antibody-drug conjugate (ADC) research collaboration, under which Genmab will use SGI's ADC technology with its HuMax-TF antibody targeting the Tissue Factor antigen in solid tumors.
Read More »
September 14, 2010
GenVec, Inc. has achieved the first milestone in its collaboration with Novartis aimed at developing treatments for hearing loss and balance disorders.
Read More »
September 13, 2010
Will evaluate CR formulation for Top 5 pharma
Read More »
September 10, 2010
Argenta, a service division of Galapagos NV, has signed a contract extension with Genentech, allowing projects to be assigned to Galapagos’ service division, BioFocus.
Read More »
September 9, 2010
DSM BioSolutions, DSM’s microbial fermentation CMO business unit, and PolyTherics Ltd. have entered into an agreement for the process development and manufacture of PolyTherics’ lead “biobetter” product, HiPEG IFN α-2a.
Read More »
September 9, 2010
Shire has licensed the activin receptor type IIB (ActRIIB) class of molecules being developed for the potential treatment of Duchenne Muscular Dystrophy (DMD), from Acceleron Pharma, Inc.
Read More »
September 2, 2010
Takeda Pharmaceutical Co. Ltd. has entered into an exclusive partnership to develop and commercialize Contrave (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the U.S., Canada and Mexico.
Read More »
August 31, 2010
Bronchitol expected to launch in EU in 2011
Read More »
August 30, 2010
Contract service providers unite to streamline CMC, regulatory access.
Read More »
August 27, 2010
Catalent Pharma Solutions has successfully completed its collaboration with BioAlliance Pharma following the launch of Miconazole.
Read More »
August 25, 2010
Sartorius Stedim Biotech and SAFC Biosciences, a member of the Sigma-Aldrich group, have signed a global partnership agreement that combines Sartorius’ expertise in filtration and liquid handling systems with SAFC’s proficiency in development
Read More »
August 24, 2010
Aileron Therapeutics and Roche have entered into a collaboration to discover, develop and commercialize a new class of drugs called Stapled Peptide Therapeutics.
Read More »
August 24, 2010
3SBio, Inc. and Isotechnika Pharma, Inc. have signed a development and commercialization agreement for voclosporin, a next-gen calcineurin inhibitor being developed for the prevention of organ rejection and the treatment of autoimmune diseases.
Read More »
August 19, 2010
Novozymes Biopharma and SAFC, a member of the Sigma-Aldrich Group, have extended by 10 years their joint agreement for LONG R3.
Read More »
August 18, 2010
Quark Pharmaceuticals has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002 currently in Phase II development.
Read More »
541 - 555 of 1091 results
